Can In-111-DTPA-octreotide (In-oC) predict kidney and tumor exposure during treatment with Y-90-SMT487 (OctreoTher (TM))?

Barone, Raffaella; Jamar, François; Pauwels, Stanislas; Walrand, Stéphan; Labar, Daniel; Carlier, Pascal; Smith, C; Kvols, L; Krenning, EP

Can In-111-DTPA-octreotide (In-oC) predict kidney and tumor exposure during treatment with Y-90-SMT487 (OctreoTher (TM))?

Barone, Raffaella

;

Jamar, François

;

Pauwels, Stanislas

;

Walrand, Stéphan

;

Krenning, EP

;et.al.

(2000)

Files

No attached file found for this publication.

Details

Authors

Barone, RaffaellaUCLouvain
Author
Jamar, FrançoisUCLouvain
Author
Pauwels, StanislasUCLouvain
Author
Walrand, StéphanUCLouvain
Author
Labar, DanielUCLouvain
Author
Carlier, PascalUCLouvain
Author
Krenning, EP
Author

Affiliations

UCLouvainCliniques universitaires Saint-Luc
UCLouvainMD/MINT - Département de médecine interne

Citations

APA
Chicago
FWB

Barone, R., Jamar, F., Pauwels, S., Walrand, S., Labar, D., Carlier, P., Smith, C., Kvols, L., & Krenning, E. (2000). Can In-111-DTPA-octreotide (In-oC) predict kidney and tumor exposure during treatment with Y-90-SMT487 (OctreoTher (TM))? The Journal of Nuclear Medicine, 41(5), 110P-111P. (Original work published 2000)